Silence Therapeutics PLC Participation at RBC Virtual Healthcare Conference
May 14 2020 - 2:00AM
RNS Non-Regulatory
TIDMSLN
Silence Therapeutics PLC
14 May 2020
Silence Therapeutics to Participate in Fireside Chat at the RBC
Capital Markets Global Healthcare Virtual Conference
14 May 2020
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the
Company"), a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases, today
announces that Dr. Rob Quinn, Chief Financial Officer, will be
participating in a fireside chat at the 2020 RBC Capital Markets
Global Healthcare Virtual Conference.
Date: Wednesday, May 20, 2020
Time: 10:55 am EDT (15:55 BST)
Webcast Silence Therapeutics fireside chat
link:
A live webcast of the event can be accessed via the Investors
section of the Company's website at
www.silence-therapeutics.com . An archived replay of the webcast
will be available for 60 days on the Company's website after the
conference.
For more information, please contact:
Silence Therapeutics plc Tel: +44 (0)20 3457
Iain Ross, Executive Chairman 6900
Rob Quinn, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418
James Steel/Oliver Jackson 8900
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
U.S. IR Tel: +1 (443) 213-0505
Westwicke
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-associated proteins. Silence's proprietary
RNA chemistries and delivery systems are designed to improve the
stability of molecules and enhance effective delivery to target
cells, providing a powerful modular technology well suited to
tackle life-threatening diseases. The Company has secured high
value research and collaboration agreements with AstraZeneca,
Mallinckrodt Pharmaceuticals and Takeda. For more information,
please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAAJMLTMTIBBLM
(END) Dow Jones Newswires
May 14, 2020 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2024 to Jun 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Jun 2023 to Jun 2024